Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This randomized, phase III trial was designed to test the efficacy of a low-dose
chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered
following standard chemotherapy in patients with early breast cancer whose tumors are hormone
receptor negative.